Ignite Creation Date:
2024-05-06 @ 7:51 AM
Last Modification Date:
2024-10-26 @ 11:53 AM
Study NCT ID:
NCT02618122
Status:
COMPLETED
Last Update Posted:
2020-11-30
First Post:
2015-11-25
Brief Title:
A Multicenter Prospective oBservational Study to assEss the Clinical activitY and Impact on symptOm Burden and patieNts HRQoL of Treatment With trabecteDin in aSTS in a Real World Setting in Greece
Sponsor:
Genesis Pharma SA
Organization:
Genesis Pharma SA
Study Overview
Official Title:
A Multicenter Prospective oBservational Study to assEss the Clinical activitY and the Impact on symptOm Burden and patieNts HRQoL of Treatment With trabecteDin in Advanced Soft Tissue Sarcomas in a Real World Setting in Greece The beYOND-STS Study
Status:
COMPLETED
Status Verified Date:
2020-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
beYOND-STS
Brief Summary:
This non-interventional study aims primarily at assessing the clinical effectiveness and the impact of the therapy on cancer-related symptoms and patients HRQoL In addition it represents an attempt towards gaining experience on the routine use of trabectedin in daily clinical practice in a representative sample of Greek subjects with aSTS
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None